Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ERBB2-Negative Early Breast Cancer
Sign Up to like & getrecommendations! Published in 2025 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2025.3700
Abstract: This exploratory 4-year analysis of the NATALEE randomized clinical trial evaluates efficacy and safety of adjuvant ribociclib beyond the planned 3-year treatment period. read more here.
Keywords: therapy hormone; hormone receptor; ribociclib plus; endocrine therapy ... See more keywords
Evaluation of Absolute Oral Bioavailability and Bioequivalence of Ribociclib, a Cyclin‐Dependent Kinase 4/6 Inhibitor, in Healthy Subjects
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.853
Abstract: Ribociclib, a selective and potent cyclin‐dependent kinase 4/6 inhibitor, has demonstrated safety and efficacy in combination with endocrine therapy in hormone receptor‐positive, human epidermal growth factor receptor‐2‐negative advanced breast cancer. In 2 open‐label crossover studies… read more here.
Keywords: bioequivalence; cyclin dependent; bioavailability; kinase inhibitor ... See more keywords
Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)
Sign Up to like & getrecommendations! Published in 2025 at "NPJ Breast Cancer"
DOI: 10.1038/s41523-024-00708-5
Abstract: Optimal timing and dosing of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor in early breast cancer is controversial. This prospective phase II clinical trial investigated tolerability and safety of two ribociclib dosing schedules. Patients with stage… read more here.
Keywords: breast cancer; cyclin dependent; breast; dependent kinase ... See more keywords
Preclinical evaluation of ribociclib and its synergistic effect in combination with alpelisib in non-keratinizing nasopharyngeal carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Scientific Reports"
DOI: 10.1038/s41598-018-26201-1
Abstract: Ribociclib is a specific cyclin dependent kinase (Cdk) 4/6 inhibitor that induces G1 arrest by blocking the formation of cyclin D1-Cdk4/6 complex and inhibiting retinoblastoma (RB) phosphorylation. Cyclin D1 is overexpressed in over 90% of… read more here.
Keywords: evaluation ribociclib; nasopharyngeal carcinoma; alpelisib; ribociclib ... See more keywords
Ribociclib-Induced Delayed Dermatological Reaction: Case Report of a Rare Adverse Effect and Review of Literature
Sign Up to like & getrecommendations! Published in 2023 at "Indian Journal of Medical and Paediatric Oncology"
DOI: 10.1055/s-0043-1766128
Abstract: Abstract Ribociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor approved in combination with endocrine-based therapy for the treatment of hormone receptor-positive (HR + )/human epidermal growth factor receptor 2-negative (HER2 − ) advanced or metastatic breast cancer. It… read more here.
Keywords: effect; induced delayed; ribociclib induced; ribociclib ... See more keywords
Effect of adenosine triphosphate on ribociclib-induced skin toxicity in rats
Sign Up to like & getrecommendations! Published in 2023 at "Cutaneous and Ocular Toxicology"
DOI: 10.1080/15569527.2023.2166524
Abstract: Abstract Purpose Ribociclib is a CDK4/6 inhibitor approved for the treatment of breast cancer; it inhibits the activity of CDK4/6 by competitively binding to adenosine 5'-triphosphate (ATP) binding sites. Although generally well-tolerated, ribociclib has been… read more here.
Keywords: induced skin; ribociclib induced; ribociclib; group ... See more keywords
Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx226
Abstract: The treatment landscape for advanced breast cancer has changed radically over the last 30–40 years with the refinement of surgical and radiographic techniques, approval of a range of chemotherapy regimens in the adjuvant and metastatic settings,… read more here.
Keywords: breast; advanced breast; breast cancer; ribociclib ... See more keywords
Should the Use of Acid Reducing Agents in Conjunction with Ribociclib be Avoided? An Integrated QbD Approach for Assessment of pH-Mediated Interaction.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of chromatographic science"
DOI: 10.1093/chromsci/bmac084
Abstract: The objective of the study was to evaluate the possible pH-dependent interaction of ribociclib succinate with acid-reducing agents, which are concomitantly administered as supportive care medicines in cancer. Quality by Design-based analytical method development for… read more here.
Keywords: interaction; ribociclib succinate; acid reducing; ribociclib ... See more keywords
Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Science"
DOI: 10.1111/cas.14554
Abstract: The ongoing, Phase Ib MONALEESASIA study is evaluating the efficacy and safety of ribociclib plus endocrine therapy in Asian patients with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer. Eligible patients from… read more here.
Keywords: endocrine therapy; phase; japanese patients; plus endocrine ... See more keywords
Cyclin-dependent kinase 4/6 inhibitor ribociclib-induced colitis with a successful transition to palbociclib
Sign Up to like & getrecommendations! Published in 2025 at "BMJ Case Reports"
DOI: 10.1136/bcr-2024-263176
Abstract: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6Is), including ribociclib, are used alongside endocrine therapy for hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative metastatic breast cancer. Ribociclib-induced colitis is a rare drug reaction with unknown… read more here.
Keywords: cyclin dependent; ribociclib induced; dependent kinase; ribociclib ... See more keywords
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-0645
Abstract: Purpose: Resistance to treatment with endocrine therapy in patients with HR+, HER2− advanced breast cancer (ABC) is common and dual inhibition of CDK4/6 and PI3K pathways may delay the development of resistance. This phase Ib… read more here.
Keywords: ribociclib; ribociclib plus; cancer; fulvestrant ribociclib ... See more keywords